Novo Nordisk A/S
CSE:NOVO B

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
CSE:NOVO B
Watchlist
Price: 589.2 DKK -20.72% Market Closed
Market Cap: 2.6T DKK
Have any thoughts about
Novo Nordisk A/S?
Write Note

Novo Nordisk A/S
Long-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Novo Nordisk A/S
Long-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
Novo Nordisk A/S
CSE:NOVO B
Long-Term Investments
kr2B
CAGR 3-Years
5%
CAGR 5-Years
0%
CAGR 10-Years
10%
H Lundbeck A/S
CSE:HLUN A
Long-Term Investments
kr99m
CAGR 3-Years
-5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ALK-Abello A/S
CSE:ALK B
Long-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Stenocare A/S
CSE:STENO
Long-Term Investments
kr494.4k
CAGR 3-Years
0%
CAGR 5-Years
142%
CAGR 10-Years
N/A
No Stocks Found

Novo Nordisk A/S
Glance View

Market Cap
2.6T DKK
Industry
Pharmaceuticals
Economic Moat
Wide

In the heart of Denmark, Novo Nordisk A/S stands as a beacon of innovation in the pharmaceutical industry, tracing its roots back to the early 20th century when it began as a small insulin-producing laboratory. This company, now a global heavyweight, is renowned for its dedication to diabetes care, a commitment that has driven its meteoric rise. Novo Nordisk's operations are deeply entrenched in the discovery, development, and production of medicines aimed at treating chronic diseases such as diabetes, obesity, and rare blood and endocrine disorders. Their prowess in biotechnology is not only evident in their diverse product portfolio but also in their relentless pursuit of new therapeutics through cutting-edge research and development, underscoring their mantra of improving the quality of life for millions across the globe. At its core, Novo Nordisk's business model is a sophisticated blend of patient-centric innovation and strategic market outreach. Sales of insulin and GLP-1 receptor agonists form the backbone of their revenue, targeting a growing global demographic faced with diabetes and related metabolic conditions. Their manufacturing process is a finely-tuned system that transforms complex scientific discoveries into tangible, effective treatments. Through strategic pricing, partnerships, and expansion in both mature and emerging markets, Novo Nordisk skillfully maneuvers the intricate web of global healthcare demands. By leveraging a robust pipeline of new drugs and improving access to existing therapies, the company not only secures its financial health but also ensures that its impact on healthcare remains profound and far-reaching.

NOVO B Intrinsic Value
683.36 DKK
Undervaluation 14%
Intrinsic Value
Price

See Also

What is Novo Nordisk A/S's Long-Term Investments?
Long-Term Investments
2B DKK

Based on the financial report for Sep 30, 2024, Novo Nordisk A/S's Long-Term Investments amounts to 2B DKK.

What is Novo Nordisk A/S's Long-Term Investments growth rate?
Long-Term Investments CAGR 10Y
10%

Over the last year, the Long-Term Investments growth was 39%. The average annual Long-Term Investments growth rates for Novo Nordisk A/S have been 5% over the past three years , and 10% over the past ten years .

Back to Top